Durila Miroslav, Lukáš Pavel, Astraverkhava Marta, Vymazal Tomáš
Department of Anaesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University in Prague, Motol University Hospital , Prague , Czech Republic.
Scand J Clin Lab Invest. 2015 Sep;75(5):407-14. doi: 10.3109/00365513.2015.1031694. Epub 2015 Apr 18.
Hypothermic coagulopathy is very challenging in bleeding trauma patients. Therefore, we decided to evaluate the efficacy of fibrinogen and prothrombin complex in 30°C hypothermia in vitro to investigate if higher levels of fibrinogen and prothrombin complex concentrate can compensate for the hypothermic effect on coagulation as measured by thromboelastometry/thromboelastography.
Blood samples were obtained from 12 healthy volunteers (six men and six women) in our study. Measurements were performed at 37°C and 30°C simultaneously, then at 30°C with adding fibrinogen and prothrombin complex and in the last step samples with added coagulation factors were warmed back to 37°C.
We found that 30°C hypothermic coagulopathy can be detected both by thromboelastometry and thromboelastography. Hypothermic coagulopathy can be restored by fibrinogen to the point where the results do not significantly differ from 37°C values (p > 0.05). After warming the sample with fibrinogen to 37°C, the thrombodynamic potential index was not significantly different from baseline (p > 0.05), although there was a trend to prothrombotic status. The addition of prothrombin complex concentrate to 30°C hypothermic sample was not able to correct hypothermic coagulopathy in vitro.
Coagulopathy caused by the 30°C hypothermia in vitro model can be corrected by fibrinogen concentrate compared to prothrombin complex concentrate. In spite of a tendency to prothrombotic status, this was not significant with the use of the recommended dose of fibrinogen even after warming the blood to 37°C. However, measurement performed at 37°C seems to be safer than at 30°C.
低温凝血障碍对于出血性创伤患者极具挑战性。因此,我们决定评估纤维蛋白原和凝血酶原复合物在30°C低温环境下的体外疗效,以研究更高水平的纤维蛋白原和凝血酶原复合物浓缩物是否能够补偿低温对凝血的影响(通过血栓弹力图/血栓弹性描记法测量)。
在我们的研究中,从12名健康志愿者(6名男性和6名女性)采集血样。同时在37°C和30°C进行测量,然后在30°C添加纤维蛋白原和凝血酶原复合物,最后一步将添加了凝血因子的样本回温至37°C。
我们发现,30°C低温凝血障碍可通过血栓弹力图和血栓弹性描记法检测到。纤维蛋白原可恢复低温凝血障碍,使结果与37°C时的值无显著差异(p>0.05)。在用纤维蛋白原将样本回温至37°C后,血栓动力学潜能指数与基线无显著差异(p>0.05),尽管有血栓形成倾向。向30°C低温样本中添加凝血酶原复合物浓缩物无法在体外纠正低温凝血障碍。
与凝血酶原复合物浓缩物相比,纤维蛋白原浓缩物可纠正体外30°C低温模型引起的凝血障碍。尽管有血栓形成倾向,但即使将血液回温至37°C,使用推荐剂量的纤维蛋白原时这种倾向也不显著。然而,在37°C进行测量似乎比在30°C更安全。